https://m2.mtmt.hu/ hun 2026-10-25 04:54 JournalArticle 34664932 VALIDATED true 0 false 2026-10-24T06:53:53.506+0000 2024-09-23T16:37:37.318+0000 2024-02-22T03:15:03.609+0000 true 10028758 Varga János Tamás /api/author/10028758 Author Varga János Tamás (pulmonológia, pulm. rehabilitáció) true 10028758 2025-01-08T14:16:57.422+0000 2024-03-18T08:03:22.050+0000 true 10083973 Szalai Fruzsina /api/admin/10083973 Admin Szalai Fruzsina (SZTE admin5-INAKTÍV) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Paróczai, Dóra true true /api/journal/10054162 REVIEWED VACCINES (BASEL) 2076-393X true false 10054162 false 10054162 true 2076-393X Journal FOREIGN 12 2 213 213 17 2024 Chronic obstructive pulmonary disease (COPD) is a frequent, often progressive, chronic disease of the lungs. Patients with COPD often have impaired immunity; therefore, they are prone to chest infections, such as pneumonia or bronchitis. Acute exacerbations of COPD are major events that accelerate disease progression, contributing to its symptoms’ burden, morbidity, and mortality. Both pneumonia and acute exacerbations in COPD are caused by bacteria against which there are effective vaccinations. Although the number of randomised controlled studies on bacterial vaccinations in COPD is limited, national and international guidelines endorse specific vaccinations in patients with COPD. This review will summarise the different types of vaccinations that prevent pneumonia and COPD exacerbations. We also discuss the results of early phase studies. We will mainly focus on Streptococcus pneumoniae, as this bacterium was predominantly investigated in COPD. However, we also review studies investigating vaccinations against Haemophilus influenzae, Moraxella catarrhalis, and Bordetella pertussis. true 2024 true true true false true false GOLD 2026-10-24 true http://publicatio.bibl.u-szeged.hu/29871 9 0 9 9 0 9 9 7 8 8 8 8 8 9 0 0 9 9 9 9 0 2 2 Folyóiratcikk Journal Article 24 9 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 3 3 3 3 2025 0 5 5 5 5 2026 0 1 1 1 1 Q1 false 10000069,10059782 false false false 2024-03-17T08:03:21.553+0000 Orvosi Mikrobiológiai Intézet (SZTE / SZAOK); Tüdőgyógyászati Klinika (SZTE / SZAOK) 3 18 2 3 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 115123182 /api/authorship/115123182 Paróczai, Dóra [Paróczai, Dóra (mikrobiológia, pu...), szerző] Orvosi Mikrobiológiai Intézet (SZTE / SZAOK); Tüdőgyógyászati Klinika (SZTE / SZAOK) 1 0.333 true false false Author 10059782 /api/author/10059782 Paróczai Dóra (mikrobiológia, pulmonológia) Paróczai Dóra true 10059782 true Paróczai Dóra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115123183 /api/authorship/115123183 Burian, Katalin [Burián, Katalin (orvosi mikrobiológia), szerző] Orvosi Mikrobiológiai Intézet (SZTE / SZAOK) 2 0.333 false false false Author 10000069 /api/author/10000069 Burián Katalin (orvosi mikrobiológia) Burián Katalin true 10000069 true Burian Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115123184 /api/authorship/115123184 Bikov, Andras ✉ [Bikov, András (Pulmonológia), szerző] 3 0.333 false true true Author 10023975 /api/author/10023975 Bikov András (Pulmonológia) Bikov András true 10023975 true Bikov Andras true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 25691658 /api/publicationidentifier/25691658 DOI: 10.3390/vaccines12020213 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/vaccines12020213 https://doi.org/10.3390/vaccines12020213 false true PublicationIdentifier 25877614 /api/publicationidentifier/25877614 WoS: 001172729400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001172729400001 https://www.webofscience.com/wos/woscc/full-record/001172729400001 false true PublicationIdentifier 25877615 /api/publicationidentifier/25877615 Scopus: 85185688819 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85185688819 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85185688819 false true PublicationIdentifier 25877616 /api/publicationidentifier/25877616 PubMed: 38400196 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38400196 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38400196&dopt=Abstract false true PublicationIdentifier 25691659 /api/publicationidentifier/25691659 Egyéb URL: https://www.mdpi.com/2076-393X/12/2/213 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true https://www.mdpi.com/2076-393X/12/2/213 https://www.mdpi.com/2076-393X/12/2/213 false true PublicationIdentifier 25872836 /api/publicationidentifier/25872836 SZTE Publicatio: 29871 SwordSource 90 /api/publicationsource/90 SZTE Publicatio PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true SZTE Publicatio SZTE Publicatio http://publicatio.bibl.u-szeged.hu/@@@ true true 90 true GREEN true IDENTICAL 29871 http://publicatio.bibl.u-szeged.hu/29871 false true Classification 12124 /api/classification/12124 Orvos- és egészségtudomány true true SjrRating 11456093 /api/sjrrating/11456093 sjr:Q1 (2024) Scopus - Drug Discovery VACCINES (BASEL) 2076-393X 38 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3002 /api/classificationexternal/3002 Scopus - Drug Discovery true 3002 true Q1 DIRECT true true Reference 50361527 /api/reference/50361527 1. (2023, July 08). 2023 GOLD Report. Available online: https://goldcopd.org/2023-gold-report-2/. 1 false true Reference 50361528 /api/reference/50361528 2. Salcedo 2005: Severe Acute Exacerbations and Mortality in Patients with Chronic Obstructive Pulmonary Disease., Thorax, 60, p. 925, DOI: 10.1136/thx.2005.040527 2 10.1136/thx.2005.040527 false true Reference 50361529 /api/reference/50361529 3. Bafadhel 2011: Acute Exacerbations of Chronic Obstructive Pulmonary Disease., Am. J. Respir. Crit. Care Med., 184, p. 662, DOI: 10.1164/rccm.201104-0597OC 3 10.1164/rccm.201104-0597OC false true Reference 50361530 /api/reference/50361530 4. Barnes 2015: Chronic Obstructive Pulmonary Disease., Nat. Rev. Dis. Primers, 1, p. 15076, DOI: 10.1038/nrdp.2015.76 4 10.1038/nrdp.2015.76 false true Reference 50361531 /api/reference/50361531 5. Hussell 2014: Alveolar Macrophages: Plasticity in a Tissue-Specific Context., Nat. Rev. Immunol., 14, p. 81, DOI: 10.1038/nri3600 5 10.1038/nri3600 false true Reference 50361532 /api/reference/50361532 6. Berenson 2013: Phagocytic Dysfunction of Human Alveolar Macrophages and Severity of Chronic Obstructive Pulmonary Disease., J. Infect. Dis., 208, p. 2036, DOI: 10.1093/infdis/jit400 6 10.1093/infdis/jit400 false true Reference 50361533 /api/reference/50361533 7. Berenson 2014: Impaired Innate Immune Alveolar Macrophage Response and the Predilection for COPD Exacerbations., Thorax, 69, p. 811, DOI: 10.1136/thoraxjnl-2013-203669 7 10.1136/thoraxjnl-2013-203669 false true Reference 50361534 /api/reference/50361534 8. Crim 2009: Pneumonia Risk in COPD Patients Receiving Inhaled Corticosteroids Alone or in Combination: TORCH Study Results., Eur. Respir. J., 34, p. 641, DOI: 10.1183/09031936.00193908 8 10.1183/09031936.00193908 false true Reference 50361535 /api/reference/50361535 9. Yang 2019: Inhaled Corticosteroids and Risk of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials., Int. Immunopharmacol., 77, p. 105950, DOI: 10.1016/j.intimp.2019.105950 9 10.1016/j.intimp.2019.105950 false true Reference 50361536 /api/reference/50361536 10. Sonnappa, S., Martin, R., Israel, E., Postma, D., van Aalderen, W., Burden, A., Usmani, O.S., Price, D.B., and on behalf of the Respiratory Effectiveness Group, S.A.S.G. (2017). Risk of Pneumonia in Obstructive Lung Disease: A Real-Life Study Comparing Extra-Fine and Fine-Particle Inhaled Corticosteroids. PLoS ONE, 12., DOI: 10.1371/journal.pone.0178112 10 10.1371/journal.pone.0178112 false true Reference 50361537 /api/reference/50361537 11. Albert 2011: Azithromycin for Prevention of Exacerbations of COPD., N. Engl. J. Med., 365, p. 689, DOI: 10.1056/NEJMoa1104623 11 10.1056/NEJMoa1104623 false true Reference 50361538 /api/reference/50361538 12. (2023, December 17). Examples: Complete Pneumococcal Vaccine Schedules for Adults, Available online: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumo-vaccine-timing.html. 12 false true Reference 50361539 /api/reference/50361539 13. Sethi 2006: Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease., Am. J. Respir. Crit. Care Med., 173, p. 991, DOI: 10.1164/rccm.200509-1525OC 13 10.1164/rccm.200509-1525OC false true Reference 50361540 /api/reference/50361540 14. Sethi 2008: Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease., N. Engl. J. Med., 359, p. 2355, DOI: 10.1056/NEJMra0800353 14 10.1056/NEJMra0800353 false true Reference 50361541 /api/reference/50361541 15. Huang 2010: A Persistent and Diverse Airway Microbiota Present during Chronic Obstructive Pulmonary Disease Exacerbations., OMICS, 14, p. 9, DOI: 10.1089/omi.2009.0100 15 10.1089/omi.2009.0100 false true Reference 50361542 /api/reference/50361542 16. Shukla 2016: Platelet-Activating Factor Receptor (PAFr) Is Upregulated in Small Airways and Alveoli of Smokers and COPD Patients., Respirology, 21, p. 504, DOI: 10.1111/resp.12709 16 10.1111/resp.12709 false true Reference 50361543 /api/reference/50361543 17. Shukla 2017: The Main Rhinovirus Respiratory Tract Adhesion Site (ICAM-1) Is Upregulated in Smokers and Patients with Chronic Airflow Limitation (CAL)., Respir. Res., 18, p. 6, DOI: 10.1186/s12931-016-0483-8 17 10.1186/s12931-016-0483-8 false true Reference 50361544 /api/reference/50361544 18. Papi 2006: Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations., Am. J. Respir. Crit. Care Med., 173, p. 1114, DOI: 10.1164/rccm.200506-859OC 18 10.1164/rccm.200506-859OC false true Reference 50361545 /api/reference/50361545 19. Celli 2007: Exacerbations of Chronic Obstructive Pulmonary Disease., Eur. Respir. J., 29, p. 1224, DOI: 10.1183/09031936.00109906 19 10.1183/09031936.00109906 false true Reference 50361546 /api/reference/50361546 20. Geno 2015: Pneumococcal Capsules and Their Types: Past, Present, and Future., Clin. Microbiol. Rev., 28, p. 871, DOI: 10.1128/CMR.00024-15 20 10.1128/CMR.00024-15 false true Reference 50361547 /api/reference/50361547 21. Lefebvre 2014: Impact of Pneumococcal Vaccines Use on Invasive Pneumococcal Disease in Nunavik (Quebec) from 1997 to 2010., Int. J. Circumpolar Health, 73, p. 22691, DOI: 10.3402/ijch.v73.22691 21 10.3402/ijch.v73.22691 false true Reference 50361548 /api/reference/50361548 22. Aliberti 2014: The Role of Vaccination in Preventing Pneumococcal Disease in Adults., Clin. Microbiol. Infect., 20, p. 52, DOI: 10.1111/1469-0691.12518 22 10.1111/1469-0691.12518 false true Reference 50361549 /api/reference/50361549 23. Wyres 2013: Pneumococcal Capsular Switching: A Historical Perspective., J. Infect. Dis., 207, p. 439, DOI: 10.1093/infdis/jis703 23 10.1093/infdis/jis703 false true Reference 50361550 /api/reference/50361550 24. Golden 2018: Molecular Characterization of Predominant Streptococcus Pneumoniae Serotypes Causing Invasive Infections in Canada: The SAVE Study, 2011–2015., J. Antimicrob. Chemother., 73, p. vii20, DOI: 10.1093/jac/dky157 24 10.1093/jac/dky157 false true Reference 50361551 /api/reference/50361551 25. Masomian, M., Ahmad, Z., Gew, L.T., and Poh, C.L. (2020). Development of Next Generation Streptococcus Pneumoniae Vaccines Conferring Broad Protection. Vaccines, 8., DOI: 10.3390/vaccines8010132 25 10.3390/vaccines8010132 false true Reference 50361552 /api/reference/50361552 26. Matanock 2019: Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices., MMWR Morb. Mortal. Wkly. Rep., 68, p. 1069, DOI: 10.15585/mmwr.mm6846a5 26 10.15585/mmwr.mm6846a5 false true Reference 50361553 /api/reference/50361553 27. Huss 2009: Efficacy of Pneumococcal Vaccination in Adults: A Meta-Analysis., CMAJ, 180, p. 48, DOI: 10.1503/cmaj.080734 27 10.1503/cmaj.080734 false true Reference 50361554 /api/reference/50361554 28. Tin Tin Htar, M., Stuurman, A.L., Ferreira, G., Alicino, C., Bollaerts, K., Paganino, C., Reinert, R.R., Schmitt, H.-J., Trucchi, C., and Vestraeten, T. (2017). Effectiveness of Pneumococcal Vaccines in Preventing Pneumonia in Adults, a Systematic Review and Meta-Analyses of Observational Studies. PLoS ONE, 12., DOI: 10.1371/journal.pone.0177985 28 10.1371/journal.pone.0177985 false true Reference 50361555 /api/reference/50361555 29. Hung 2010: A 5-Year Longitudinal Follow-up Study of Serological Responses to 23-Valent Pneumococcal Polysaccharide Vaccination among Patients with HIV Infection Who Received Highly Active Antiretroviral Therapy., HIV Med., 11, p. 54, DOI: 10.1111/j.1468-1293.2009.00744.x 29 10.1111/j.1468-1293.2009.00744.x false true Reference 50361556 /api/reference/50361556 30. Musher 1992: Antibody to Capsular Polysaccharides of Streptococcus Pneumoniae after Vaccination of Human Immunodeficiency Virus-Infected Subjects with 23-Valent Pneumococcal Vaccine., J. Infect. Dis., 165, p. 553, DOI: 10.1093/infdis/165.3.553 30 10.1093/infdis/165.3.553 false true Reference 50361557 /api/reference/50361557 31. Clutterbuck 2012: Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells., J. Infect. Dis., 205, p. 1408, DOI: 10.1093/infdis/jis212 31 10.1093/infdis/jis212 false true Reference 50361558 /api/reference/50361558 32. Ingels, H.A.S., Kantsø, B., and Slotved, H.-C. (2018). Serologic Response to Pneumococcal Vaccination in Children Experiencing Recurrent Invasive Pneumococcal Disease. BMC Infect. Dis., 18., DOI: 10.1186/s12879-018-3267-6 32 10.1186/s12879-018-3267-6 false true Reference 50361559 /api/reference/50361559 33. Lazarus 2011: A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults., Clin. Infect. Dis., 52, p. 736, DOI: 10.1093/cid/cir003 33 10.1093/cid/cir003 false true Reference 50361560 /api/reference/50361560 34. Dransfield 2009: Superior Immune Response to Protein-Conjugate versus Free Pneumococcal Polysaccharide Vaccine in Chronic Obstructive Pulmonary Disease., Am. J. Respir. Crit. Care Med., 180, p. 499, DOI: 10.1164/rccm.200903-0488OC 34 10.1164/rccm.200903-0488OC false true Reference 50361561 /api/reference/50361561 35. Dransfield 2012: Long-Term Comparative Immunogenicity of Protein Conjugate and Free Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease., Clin. Infect. Dis., 55, p. e35, DOI: 10.1093/cid/cis513 35 10.1093/cid/cis513 false true Reference 50361562 /api/reference/50361562 36. Goldblatt 2000: Conjugate Vaccines., Clin. Exp. Immunol., 119, p. 1, DOI: 10.1046/j.1365-2249.2000.01109.x 36 10.1046/j.1365-2249.2000.01109.x false true Reference 50361563 /api/reference/50361563 37. Prymula 2009: 10-Valent Pneumococcal Nontypeable Haemophilus Influenzae PD Conjugate Vaccine: Synflorix., Expert. Rev. Vaccines, 8, p. 1479, DOI: 10.1586/erv.09.113 37 10.1586/erv.09.113 false true Reference 50361564 /api/reference/50361564 38. (2012). Centers for Disease Control and Prevention (CDC) Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep., 61, 816–819. 38 false true Reference 50361565 /api/reference/50361565 39. Schwarz 2011: A Randomized, Double-Blind Trial to Evaluate Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine given Concomitantly with Trivalent Influenza Vaccine in Adults Aged ≥65 Years., Vaccine, 29, p. 5195, DOI: 10.1016/j.vaccine.2011.05.031 39 10.1016/j.vaccine.2011.05.031 false true Reference 50361566 /api/reference/50361566 40. Walters 2010: Injectable Vaccines for Preventing Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease., Cochrane Database Syst. Rev., 10, p. CD001390 40 false true Reference 50361567 /api/reference/50361567 41. Steentoft 2006: Response to Pneumococcal Vaccine in Chronic Obstructive Lung Disease--the Effect of Ongoing, Systemic Steroid Treatment., Vaccine, 24, p. 1408, DOI: 10.1016/j.vaccine.2005.09.020 41 10.1016/j.vaccine.2005.09.020 false true Reference 50361568 /api/reference/50361568 42. Walters 2017: Pneumococcal Vaccines for Preventing Pneumonia in Chronic Obstructive Pulmonary Disease., Cochrane Database Syst. Rev., 1, p. CD001390 42 false true Reference 50361569 /api/reference/50361569 43. Alfageme 2006: Clinical Efficacy of Anti-Pneumococcal Vaccination in Patients with COPD., Thorax, 61, p. 189, DOI: 10.1136/thx.2005.043323 43 10.1136/thx.2005.043323 false true Reference 50361570 /api/reference/50361570 44. Ortqvist 1998: Randomised Trial of 23-Valent Pneumococcal Capsular Polysaccharide Vaccine in Prevention of Pneumonia in Middle-Aged and Elderly People. Swedish Pneumococcal Vaccination Study Group., Lancet, 351, p. 399, DOI: 10.1016/S0140-6736(97)07358-3 44 10.1016/S0140-6736(97)07358-3 false true Reference 50361571 /api/reference/50361571 45. Jackson 2003: Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults., N. Engl. J. Med., 348, p. 1747, DOI: 10.1056/NEJMoa022678 45 10.1056/NEJMoa022678 false true Reference 50361572 /api/reference/50361572 46. Grabenstein 2012: Pneumococcal Polysaccharide 23-Valent Vaccine: Long-Term Persistence of Circulating Antibody and Immunogenicity and Safety after Revaccination in Adults., Vaccine, 30, p. 4435, DOI: 10.1016/j.vaccine.2012.04.052 46 10.1016/j.vaccine.2012.04.052 false true Reference 50361573 /api/reference/50361573 47. LaFon 2023: Reduced Quantity and Function of Pneumococcal Antibodies Are Associated with Exacerbations of COPD in SPIROMICS., Clin. Immunol., 250, p. 109324, DOI: 10.1016/j.clim.2023.109324 47 10.1016/j.clim.2023.109324 false true Reference 50361574 /api/reference/50361574 48. Furumoto 2008: Additive Effect of Pneumococcal Vaccine and Influenza Vaccine on Acute Exacerbation in Patients with Chronic Lung Disease., Vaccine, 26, p. 4284, DOI: 10.1016/j.vaccine.2008.05.037 48 10.1016/j.vaccine.2008.05.037 false true Reference 50361575 /api/reference/50361575 49. Nichol 1999: The Additive Benefits of Influenza and Pneumococcal Vaccinations during Influenza Seasons among Elderly Persons with Chronic Lung Disease., Vaccine, 17, p. S91, DOI: 10.1016/S0264-410X(99)00114-0 49 10.1016/S0264-410X(99)00114-0 false true Reference 50361576 /api/reference/50361576 50. Christenson 2008: Effect of Influenza and Pneumococcal Vaccines in Elderly Persons in Years of Low Influenza Activity., Virol. J., 5, p. 52, DOI: 10.1186/1743-422X-5-52 50 10.1186/1743-422X-5-52 false true Reference 50361577 /api/reference/50361577 51. Fekete 2020: Prevalence of Influenza and Pneumococcal Vaccination in Chronic Obstructive Pulmonary Disease Patients in Association with the Occurrence of Acute Exacerbations., J. Thorac. Dis., 12, p. 4233, DOI: 10.21037/jtd-20-814 51 10.21037/jtd-20-814 false true Reference 50361578 /api/reference/50361578 52. Li 2022: Effectiveness of Influenza and Pneumococcal Vaccines on Chronic Obstructive Pulmonary Disease Exacerbations., Respirology, 27, p. 844, DOI: 10.1111/resp.14309 52 10.1111/resp.14309 false true Reference 50361579 /api/reference/50361579 53. Chen 2022: Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered with Quadrivalent Split-Virion Inactivated Influenza Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine in China: A Multicentre, Non-Inferiority, Open-Label, Randomised, Controlled, Phase 4 Trial., Vaccine, 40, p. 5322, DOI: 10.1016/j.vaccine.2022.07.033 53 10.1016/j.vaccine.2022.07.033 false true Reference 50361580 /api/reference/50361580 54. Davis 1987: Pneumococcal Infection and Immunologic Response to Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease. A Pilot Study., Chest, 92, p. 204, DOI: 10.1378/chest.92.2.204 54 10.1378/chest.92.2.204 false true Reference 50361581 /api/reference/50361581 55. Kostinov 2014: The Clinical Aspects of Efficiency of the Prevention of Pneumococcal Infection with Vaccines in Chronic Obstructive Pulmonary Disease Patients Living in the West Siberian Region., Ter. Arkhiv, 86, p. 28 55 false true Reference 50361582 /api/reference/50361582 56. Ignatova 2021: Comparative Effectiveness of Pneumococcal Vaccination with PPV23 and PCV13 in COPD Patients over a 5-Year Follow-up Cohort Study., Sci. Rep., 11, p. 15948, DOI: 10.1038/s41598-021-95129-w 56 10.1038/s41598-021-95129-w false true Reference 50361583 /api/reference/50361583 57. Black 2000: Efficacy, Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Children. Northern California Kaiser Permanente Vaccine Study Center Group., Pediatr. Infect. Dis. J., 19, p. 187, DOI: 10.1097/00006454-200003000-00003 57 10.1097/00006454-200003000-00003 false true Reference 50361584 /api/reference/50361584 58. Jackson 2007: Immunogenicity of Varying Dosages of 7-Valent Pneumococcal Polysaccharide-Protein Conjugate Vaccine in Seniors Previously Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine., Vaccine, 25, p. 4029, DOI: 10.1016/j.vaccine.2007.02.062 58 10.1016/j.vaccine.2007.02.062 false true Reference 50361585 /api/reference/50361585 59. Clutterbuck 2006: The Kinetics and Phenotype of the Human B-Cell Response Following Immunization with a Heptavalent Pneumococcal-CRM Conjugate Vaccine., Immunology, 119, p. 328, DOI: 10.1111/j.1365-2567.2006.02436.x 59 10.1111/j.1365-2567.2006.02436.x false true Reference 50361586 /api/reference/50361586 60. Siber 2008: Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory., Clin. Infect. Dis., 46, p. 1015, DOI: 10.1086/529142 60 10.1086/529142 false true Reference 50361587 /api/reference/50361587 61. Baxendale 2010: Circulating Pneumococcal Specific Plasma and Memory B Cells in the Elderly Two Years after Pneumococcal Conjugate versus Polysaccharide Vaccination., Vaccine, 28, p. 6915, DOI: 10.1016/j.vaccine.2010.08.004 61 10.1016/j.vaccine.2010.08.004 false true Reference 50361588 /api/reference/50361588 62. Baxendale 2010: The Early Kinetics of Circulating Pneumococcal-Specific Memory B Cells Following Pneumococcal Conjugate and Plain Polysaccharide Vaccines in the Elderly., Vaccine, 28, p. 4763, DOI: 10.1016/j.vaccine.2010.04.103 62 10.1016/j.vaccine.2010.04.103 false true Reference 50361589 /api/reference/50361589 63. Cheng 2016: Long-Term Immune Responses and Comparative Effectiveness of One or Two Doses of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in HIV-Positive Adults in the Era of Combination Antiretroviral Therapy., J. Int. AIDS Soc., 19, p. 20631, DOI: 10.7448/IAS.19.1.20631 63 10.7448/IAS.19.1.20631 false true Reference 50361590 /api/reference/50361590 64. Bonten 2015: Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults., N. Engl. J. Med., 372, p. 1114, DOI: 10.1056/NEJMoa1408544 64 10.1056/NEJMoa1408544 false true Reference 50361591 /api/reference/50361591 65. Suaya 2018: Post Hoc Analysis of the Efficacy of the 13-Valent Pneumococcal Conjugate Vaccine against Vaccine-Type Community-Acquired Pneumonia in at-Risk Older Adults., Vaccine, 36, p. 1477, DOI: 10.1016/j.vaccine.2018.01.049 65 10.1016/j.vaccine.2018.01.049 false true Reference 50361592 /api/reference/50361592 66. Metcalf 2016: Strain Features and Distributions in Pneumococci from Children with Invasive Disease before and after 13-Valent Conjugate Vaccine Implementation in the USA., Clin. Microbiol. Infect., 22, p. 60.e9, DOI: 10.1016/j.cmi.2015.08.027 66 10.1016/j.cmi.2015.08.027 false true Reference 50361593 /api/reference/50361593 67. Tomczyk 2016: Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine., Clin. Infect. Dis., 62, p. 1119, DOI: 10.1093/cid/ciw067 67 10.1093/cid/ciw067 false true Reference 50361594 /api/reference/50361594 68. Kobayashi 2022: Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022., MMWR Morb. Mortal. Wkly. Rep., 71, p. 109, DOI: 10.15585/mmwr.mm7104a1 68 10.15585/mmwr.mm7104a1 false true Reference 50361595 /api/reference/50361595 69. Stacey 2019: Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared to PCV-13 in Healthy Older Adults., Hum. Vaccin. Immunother., 15, p. 530, DOI: 10.1080/21645515.2018.1532249 69 10.1080/21645515.2018.1532249 false true Reference 50361596 /api/reference/50361596 70. Essink 2022: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years., Clin. Infect. Dis., 75, p. 390, DOI: 10.1093/cid/ciab990 70 10.1093/cid/ciab990 false true Reference 50361597 /api/reference/50361597 71. Hurley 2021: Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age., Clin. Infect. Dis., 73, p. e1489, DOI: 10.1093/cid/ciaa1045 71 10.1093/cid/ciaa1045 false true Reference 50361598 /api/reference/50361598 72. Thompson 2019: Coadministration of 13-Valent Pneumococcal Conjugate and Quadrivalent Inactivated Influenza Vaccines in Adults Previously Immunized with Polysaccharide Pneumococcal Vaccine 23: A Randomized Clinical Trial., Hum. Vaccin. Immunother., 15, p. 444, DOI: 10.1080/21645515.2018.1533777 72 10.1080/21645515.2018.1533777 false true Reference 50361599 /api/reference/50361599 73. Cannon 2023: Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Coadministered with Quadrivalent Influenza Vaccine: A Phase 3 Randomized Trial., Vaccine, 41, p. 2137, DOI: 10.1016/j.vaccine.2022.11.046 73 10.1016/j.vaccine.2022.11.046 false true Reference 50361600 /api/reference/50361600 74. Young 2023: Randomized Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster (Third Dose) of BNT162b2 COVID-19 Vaccine Coadministered with 20-Valent Pneumococcal Conjugate Vaccine in Adults ≥65 Years Old., Vaccine, 41, p. 4190, DOI: 10.1016/j.vaccine.2023.05.002 74 10.1016/j.vaccine.2023.05.002 false true Reference 50361601 /api/reference/50361601 75. Drame 2017: Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Co-Administered with a 23-Valent Pneumococcal Polysaccharide Vaccine versus Separate Administration, in Adults ≥50years of Age: Results from a Phase III, Randomized, Non-Inferiority Trial., Vaccine, 35, p. 6321, DOI: 10.1016/j.vaccine.2017.09.012 75 10.1016/j.vaccine.2017.09.012 false true Reference 50361602 /api/reference/50361602 76. Shoji 2018: Overview of Pneumococcal Serotypes and Genotypes Causing Diseases in Patients with Chronic Obstructive Pulmonary Disease in a Spanish Hospital between 2013 and 2016., Infect. Drug Resist., 11, p. 1387, DOI: 10.2147/IDR.S165093 76 10.2147/IDR.S165093 false true Reference 50361603 /api/reference/50361603 77. Molloy 2018: Airway Epithelium Dysfunction in Cystic Fibrosis and COPD., Mediat. Inflamm., 2018, p. 1309746 77 false true Reference 50361604 /api/reference/50361604 78. Tu 1999: Pneumococcal Surface Protein A Inhibits Complement Activation by Streptococcus Pneumoniae., Infect. Immun., 67, p. 4720, DOI: 10.1128/IAI.67.9.4720-4724.1999 78 10.1128/IAI.67.9.4720-4724.1999 false true Reference 50361605 /api/reference/50361605 79. Roche 2001: Characterization of Binding of Human Lactoferrin to Pneumococcal Surface Protein A., Infect. Immun., 69, p. 3372, DOI: 10.1128/IAI.69.5.3372-3381.2001 79 10.1128/IAI.69.5.3372-3381.2001 false true Reference 50361606 /api/reference/50361606 80. Briles 2000: Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPspA) Elicits Antibodies That Passively Protect Mice from Fatal Infection with Streptococcus Pneumoniae Bearing Heterologous PspA., J. Infect. Dis., 182, p. 1694, DOI: 10.1086/317602 80 10.1086/317602 false true Reference 50361607 /api/reference/50361607 81. Kono, M., Iyo, T., Murakami, D., Sakatani, H., Nanushaj, D., and Hotomi, M. (2023). Maternal Immunization with Pneumococcal Surface Protein A Provides the Immune Memories of Offspring against Pneumococcal Infection. Front. Cell Infect. Microbiol., 13., DOI: 10.3389/fcimb.2023.1059603 81 10.3389/fcimb.2023.1059603 false true Reference 50361608 /api/reference/50361608 82. Akbari, E., Negahdari, B., Faraji, F., Behdani, M., Kazemi-Lomedasht, F., and Habibi-Anbouhi, M. (2019). Protective Responses of an Engineered PspA Recombinant Antigen against Streptococcus Pneumoniae. Biotechnol. Rep., 24., DOI: 10.1016/j.btre.2019.e00385 82 10.1016/j.btre.2019.e00385 false true Reference 50361609 /api/reference/50361609 83. Georgieva 2018: Antigenic Variation in Streptococcus Pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity., mBio, 9, p. e00264-18, DOI: 10.1128/mBio.00264-18 83 10.1128/mBio.00264-18 false true Reference 50361610 /api/reference/50361610 84. McNeela, E.A., Burke, A., Neill, D.R., Baxter, C., Fernandes, V.E., Ferreira, D., Smeaton, S., El-Rachkidy, R., McLoughlin, R.M., and Mori, A. (2010). Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4. PLoS Pathog., 6., DOI: 10.1371/journal.ppat.1001191 84 10.1371/journal.ppat.1001191 false true Reference 50361611 /api/reference/50361611 85. Hill 2018: Immunogenicity and Mechanisms of Action of PnuBioVax, a Multi-Antigen Serotype-Independent Prophylactic Vaccine against Infection with Streptococcus Pneumoniae., Vaccine, 36, p. 4255, DOI: 10.1016/j.vaccine.2018.05.122 85 10.1016/j.vaccine.2018.05.122 false true Reference 50361612 /api/reference/50361612 86. Entwisle 2017: Safety and Immunogenicity of a Novel Multiple Antigen Pneumococcal Vaccine in Adults: A Phase 1 Randomised Clinical Trial., Vaccine, 35, p. 7181, DOI: 10.1016/j.vaccine.2017.10.076 86 10.1016/j.vaccine.2017.10.076 false true Reference 50361613 /api/reference/50361613 87. Wang 2022: Subcutaneous Immunization with the Fusion. Protein ΔA146Ply-SP0148 Confers Protection against Streptococcus Pneumoniae Infection., Microb. Pathog., 162, p. 105325, DOI: 10.1016/j.micpath.2021.105325 87 10.1016/j.micpath.2021.105325 false true Reference 50361614 /api/reference/50361614 88. Dos Santos, T.W., Gonçalves, P.A., Rodriguez, D., Pereira, J.A., Martinez, C.A.R., Leite, L.C.C., Ferraz, L.F.C., Converso, T.R., and Darrieux, M. (2022). A Fusion Protein Comprising Pneumococcal Surface Protein A and a Pneumolysin Derivate Confers Protection in a Murine Model of Pneumococcal Pneumonia. PLoS ONE, 17., DOI: 10.1371/journal.pone.0277304 88 10.1371/journal.pone.0277304 false true Reference 50361615 /api/reference/50361615 89. Bersch, B., Bougault, C., Roux, L., Favier, A., Vernet, T., and Durmort, C. (2013). New Insights into Histidine Triad Proteins: Solution Structure of a Streptococcus Pneumoniae PhtD Domain and Zinc Transfer to AdcAII. PLoS ONE, 8., DOI: 10.1371/journal.pone.0081168 89 10.1371/journal.pone.0081168 false true Reference 50361616 /api/reference/50361616 90. Khan 2013: CD4 T Cell Memory and Antibody Responses Directed against the Pneumococcal Histidine Triad Proteins PhtD and PhtE Following Nasopharyngeal Colonization and Immunization and Their Role in Protection against Pneumococcal Colonization in Mice., Infect. Immun., 81, p. 3781, DOI: 10.1128/IAI.00313-13 90 10.1128/IAI.00313-13 false true Reference 50361617 /api/reference/50361617 91. Seiberling 2012: Safety and Immunogenicity of a Pneumococcal Histidine Triad Protein D Vaccine Candidate in Adults., Vaccine, 30, p. 7455, DOI: 10.1016/j.vaccine.2012.10.080 91 10.1016/j.vaccine.2012.10.080 false true Reference 50361618 /api/reference/50361618 92. Devaster 2015: Adjuvant System AS02V Enhances Humoral and Cellular Immune Responses to Pneumococcal Protein PhtD Vaccine in Healthy Young and Older Adults: Randomised, Controlled Trials., Vaccine, 33, p. 577, DOI: 10.1016/j.vaccine.2013.10.052 92 10.1016/j.vaccine.2013.10.052 false true Reference 50361619 /api/reference/50361619 93. Brooks 2015: PPR02 Study Team Safety and Immunogenicity of a Trivalent Recombinant PcpA, PhtD, and PlyD1 Pneumococcal Protein Vaccine in Adults, Toddlers, and Infants: A Phase I Randomized Controlled Study., Vaccine, 33, p. 4610, DOI: 10.1016/j.vaccine.2015.06.078 93 10.1016/j.vaccine.2015.06.078 false true Reference 50361620 /api/reference/50361620 94. Maes 2014: Safety, Reactogenicity and Immunogenicity of a Novel Pneumococcal Protein-Based Vaccine in Adults: A Phase I/II Randomized Clinical Study., Vaccine, 32, p. 6838, DOI: 10.1016/j.vaccine.2014.02.052 94 10.1016/j.vaccine.2014.02.052 false true Reference 50361621 /api/reference/50361621 95. Nagai 2019: Immunization with Pneumococcal Elongation Factor Tu Enhances Serotype-Independent Protection against Streptococcus Pneumoniae Infection., Vaccine, 37, p. 160, DOI: 10.1016/j.vaccine.2018.11.015 95 10.1016/j.vaccine.2018.11.015 false true Reference 50361622 /api/reference/50361622 96. Cui 2022: Construction and Protective Efficacy of a Novel Streptococcus Pneumoniae Fusion Protein Vaccine NanAT1-TufT1-PlyD4., Front. Immunol., 13, p. 1043293, DOI: 10.3389/fimmu.2022.1043293 96 10.3389/fimmu.2022.1043293 false true Reference 50361623 /api/reference/50361623 97. Lu 2010: Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell Vaccine., Clin. Vaccine Immunol., 17, p. 1005, DOI: 10.1128/CVI.00036-10 97 10.1128/CVI.00036-10 false true Reference 50361624 /api/reference/50361624 98. Jang 2019: Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine With Lgt Deletion., Front. Immunol., 10, p. 1212, DOI: 10.3389/fimmu.2019.01212 98 10.3389/fimmu.2019.01212 false true Reference 50361625 /api/reference/50361625 99. Rodrigues, T.C., Oliveira, M.L.S., Soares-Schanoski, A., Chavez-Rico, S.L., Figueiredo, D.B., Gonçalves, V.M., Ferreira, D.M., Kunda, N.K., Saleem, I.Y., and Miyaji, E.N. (2018). Mucosal Immunization with PspA (Pneumococcal Surface Protein A)-Adsorbed Nanoparticles Targeting the Lungs for Protection against Pneumococcal Infection. PLoS ONE, 13., DOI: 10.1371/journal.pone.0191692 99 10.1371/journal.pone.0191692 false true Reference 50361626 /api/reference/50361626 100. Sethi 2002: New Strains of Bacteria and Exacerbations of Chronic Obstructive Pulmonary Disease., N. Engl. J. Med., 347, p. 465, DOI: 10.1056/NEJMoa012561 100 10.1056/NEJMoa012561 false true Reference 50361627 /api/reference/50361627 101. Murphy 2005: Moraxella Catarrhalis in Chronic Obstructive Pulmonary Disease: Burden of Disease and Immune Response., Am. J. Respir. Crit. Care Med., 172, p. 195, DOI: 10.1164/rccm.200412-1747OC 101 10.1164/rccm.200412-1747OC false true Reference 50361628 /api/reference/50361628 102. Murphy 2008: Pseudomonas Aeruginosa in Chronic Obstructive Pulmonary Disease., Am. J. Respir. Crit. Care Med., 177, p. 853, DOI: 10.1164/rccm.200709-1413OC 102 10.1164/rccm.200709-1413OC false true Reference 50361629 /api/reference/50361629 103. Sriram 2018: Nontypeable Haemophilus Influenzae and Chronic Obstructive Pulmonary Disease: A Review for Clinicians., Crit. Rev. Microbiol., 44, p. 125, DOI: 10.1080/1040841X.2017.1329274 103 10.1080/1040841X.2017.1329274 false true Reference 50361630 /api/reference/50361630 104. Khan 2016: Developing a Vaccine to Prevent Otitis Media Caused by Nontypeable Haemophilus Influenzae., Expert. Rev. Vaccines, 15, p. 863, DOI: 10.1586/14760584.2016.1156539 104 10.1586/14760584.2016.1156539 false true Reference 50361631 /api/reference/50361631 105. Haazen 2016: Phase I, Randomized, Observer-Blind, Placebo-Controlled Studies to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Non-Typeable Haemophilus Influenzae (NTHi) Protein Vaccine in Adults., Vaccine, 34, p. 3156, DOI: 10.1016/j.vaccine.2016.04.051 105 10.1016/j.vaccine.2016.04.051 false true Reference 50361632 /api/reference/50361632 106. Armbruster 2010: Indirect Pathogenicity of Haemophilus Influenzae and Moraxella Catarrhalis in Polymicrobial Otitis Media Occurs via Interspecies Quorum Signaling., mBio, 1, p. e00102-10, DOI: 10.1128/mBio.00102-10 106 10.1128/mBio.00102-10 false true Reference 50361633 /api/reference/50361633 107. Tan 2007: Haemophilus Influenzae Survival during Complement-Mediated Attacks Is Promoted by Moraxella Catarrhalis Outer Membrane Vesicles., J. Infect. Dis., 195, p. 1661, DOI: 10.1086/517611 107 10.1086/517611 false true Reference 50361634 /api/reference/50361634 108. Perez 2019: Do We Need a Vaccine against Moraxella Catarrhalis in Chronic Lung Disease? What Are the Options and Opportunities?., Vaccine, 37, p. 5551, DOI: 10.1016/j.vaccine.2016.12.066 108 10.1016/j.vaccine.2016.12.066 false true Reference 50361635 /api/reference/50361635 109. Vandermeulen 2019: Safety and Immunogenicity of Non-Typeable Haemophilus Influenzae-Moraxella Catarrhalis Vaccine., Vaccine, 37, p. 3113, DOI: 10.1016/j.vaccine.2019.04.041 109 10.1016/j.vaccine.2019.04.041 false true Reference 50361636 /api/reference/50361636 110. Wilkinson 2019: Non-Typeable Haemophilus Influenzae Protein Vaccine in Adults with COPD: A Phase 2 Clinical Trial., Vaccine, 37, p. 6102, DOI: 10.1016/j.vaccine.2019.07.100 110 10.1016/j.vaccine.2019.07.100 false true Reference 50361637 /api/reference/50361637 111. Andreas 2022: Non-Typeable Haemophilus Influenzae-Moraxella Catarrhalis Vaccine for the Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: A Multicentre, Randomised, Placebo-Controlled, Observer-Blinded, Proof-of-Concept, Phase 2b Trial., Lancet Respir. Med., 10, p. 435, DOI: 10.1016/S2213-2600(21)00502-6 111 10.1016/S2213-2600(21)00502-6 false true Reference 50361638 /api/reference/50361638 112. Liu 2012: Pertussis in Older Adults: Prospective Study of Risk Factors and Morbidity., Clin. Infect. Dis., 55, p. 1450, DOI: 10.1093/cid/cis627 112 10.1093/cid/cis627 false true Reference 50361639 /api/reference/50361639 113. 2022: Whooping Cough: The Visible Enemy., Arch. Bronconeumol., 58, p. 300, DOI: 10.1016/j.arbres.2021.06.021 113 10.1016/j.arbres.2021.06.021 false true Reference 50361640 /api/reference/50361640 114. Wilkinson 2021: Seroprevalence of Bordetella Pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort., COPD, 18, p. 341, DOI: 10.1080/15412555.2021.1920904 114 10.1080/15412555.2021.1920904 false true Reference 50361641 /api/reference/50361641 115. Buck 2017: Economic Burden of Diagnosed Pertussis among Individuals with Asthma or Chronic Obstructive Pulmonary Disease in the USA: An Analysis of Administrative Claims., Epidemiol. Infect., 145, p. 2109, DOI: 10.1017/S0950268817000887 115 10.1017/S0950268817000887 false true Reference 50361642 /api/reference/50361642 116. Havers 2020: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2019., MMWR Morb. Mortal. Wkly. Rep., 69, p. 77, DOI: 10.15585/mmwr.mm6903a5 116 10.15585/mmwr.mm6903a5 false true Reference 50361643 /api/reference/50361643 117. 2022: Pertussis Vaccine in COPD and Asthma: An Old Acquaintance Is Back., Open Respir. Arch., 4, p. 100153, DOI: 10.1016/j.opresp.2021.100153 117 10.1016/j.opresp.2021.100153 false true /api/publication/34664932 Paróczai Dóra et al. Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease. (2024) VACCINES (BASEL) 2076-393X 12 2<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10059782"><a href="/gui2/?type=authors&mode=browse&sel=10059782" target="_blank">Paróczai Dóra (<span class="authorship-author-name">Paróczai Dóra</span> <span class="authorAux-mtmt"> mikrobiológia, pulmonológia</span>) </a> </span> <span class="author-affil"><span title="Szegedi Tudományegyetem">SZTE</span>/<span title="Szent-Györgyi Albert Orvostudományi Kar">SZAOK</span>/Orvosi Mikrobiológiai Intézet; <span title="Szegedi Tudományegyetem">SZTE</span>/<span title="Szent-Györgyi Albert Orvostudományi Kar">SZAOK</span>/Tüdőgyógyászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000069"><a href="/gui2/?type=authors&mode=browse&sel=10000069" target="_blank">Burian Katalin (<span class="authorship-author-name">Burián Katalin</span> <span class="authorAux-mtmt"> orvosi mikrobiológia</span>) </a> </span> <span class="author-affil"><span title="Szegedi Tudományegyetem">SZTE</span>/<span title="Szent-Györgyi Albert Orvostudományi Kar">SZAOK</span>/Orvosi Mikrobiológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023975"><a href="/gui2/?type=authors&mode=browse&sel=10023975" target="_blank">Bikov Andras ✉ (<span class="authorship-author-name">Bikov András</span> <span class="authorAux-mtmt"> Pulmonológia</span>) </a> </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34664932" target="_blank">Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease</a></div> <div> <span class="journal-title">VACCINES (BASEL)</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2076-393X">2076-393X</a>)</span>: <span class="journal-volume">12</span> <span class="journal-issue">2</span> <span class="page"> Paper 213. 17 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/vaccines12020213" target="_blank" href="https://doi.org/10.3390/vaccines12020213"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001172729400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001172729400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85185688819" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85185688819"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38400196" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38400196&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="https://www.mdpi.com/2076-393X/12/2/213" target="_blank" href="https://www.mdpi.com/2076-393X/12/2/213"> Egyéb URL </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="29871" target="_blank" href="http://publicatio.bibl.u-szeged.hu/29871"> SZTE Publicatio </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Drug Discovery&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Infectious Diseases&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology (medical)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 9</span> | Független: 9 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 7 | Scopus jelölt:&nbsp;8 | WoS/Scopus jelölt:&nbsp;8 | DOI jelölt:&nbsp;9 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34664932&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34664932</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2024.09.23. 18:37 Vigyikánné Váradi Anikó (SZTE admin5 SZAOK Orvosi Mikrobiológiai Intézet) </div> </div></div>